
|Videos|November 26, 2013
Episode 12 - Specialty Pharmacy's Role in CRPC
Advertisement
Episodes in this series

While discussing channel management in urology, Jeffrey D. Dunn, PharmD, MBA, introduces specialty pharmacy’s role.
Moderator Raoul S. Concepcion, MD, explains that the concept of pharmacy benefit is relatively new in the field of urology.
Dr Dunn and Michael Kolodziej, MD, explain their concerns about treatment expenses, care management, and the challenge for clinicians to select the specialty pharmacy of their choice.
Additionally, David Quinn, MD, explains why the administration of parenteral drugs through infusion centers has become a concern to clinicians.
Advertisement
Related to this article

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5













